Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Cash And Cash Equivalents At Carrying Value of $51.09 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +124.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2016: $4.51 million | Q2 2017: $63.78 million | Q3 2017: $59.95 million | Q2 2018: $173.43 million | Q3 2018: $159.67 million | Q1 2019: $31.24 million | Q2 2019: $33.11 million | Q3 2019: $85.51 million | Q1 2020: $74.93 million | Q2 2020: $136.29 million | Q3 2020: $141.68 million | Q1 2021: $49.29 million | Q2 2021: $155.03 million | Q3 2021: $157.54 million | Q1 2022: $71.77 million | Q2 2022: $54.83 million | Q3 2022: $36.88 million | Q1 2023: $23.21 million | Q2 2023: $40.28 million | Q3 2023: $157.28 million | Q1 2024: $329.72 million | Q2 2024: $314.17 million | Q3 2024: $33.67 million | Q1 2025: $10.12 million | Q2 2025: $13.24 million | Q3 2025: $55.98 million.
- Over the full 9 years of available data (2017 to 2025), Dianthus Therapeutics, Inc. /DE/'s Cash And Cash Equivalents At Carrying Value has declined by 0.6%.
- Historical annual values: Fiscal year 2025: $51.09 million | Fiscal year 2024: $22.79 million | Fiscal year 2023: $132.33 million | Fiscal year 2022: $15.37 million | Fiscal year 2021: $131.65 million | Fiscal year 2020: $58.15 million | Fiscal year 2019: $65.07 million | Fiscal year 2018: $58.35 million | Fiscal year 2017: $51.40 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: